Loading…

Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition

To investigate immune escape during breast tumor progression, we analyzed the composition of leukocytes in normal breast tissues, ductal carcinoma (DCIS), and invasive ductal carcinomas (IDC). We found significant tissue and tumor subtype-specific differences in multiple cell types including T cells...

Full description

Saved in:
Bibliographic Details
Published in:Cancer discovery 2017-10, Vol.7 (10), p.1098-1115
Main Authors: Gil Del Alcazar, Carlos R, Huh, Sung Jin, Ekram, Muhammad B, Trinh, Anne, Liu, Lin L, Beca, Francisco, Zi, Xiaoyuan, Kwak, Minsuk, Bergholtz, Helga, Su, Ying, Ding, Lina, Russnes, Hege G, Richardson, Andrea L, Babski, Kirsten, Min Hui Kim, Elizabeth, McDonnell, 3rd, Charles H, Wagner, Jon, Rowberry, Ron, Freeman, Gordon J, Dillon, Deborah, Sorlie, Therese, Coussens, Lisa M, Garber, Judy E, Fan, Rong, Bobolis, Kristie, Allred, D Craig, Jeong, Joon, Park, So Yeon, Michor, Franziska, Polyak, Kornelia
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate immune escape during breast tumor progression, we analyzed the composition of leukocytes in normal breast tissues, ductal carcinoma (DCIS), and invasive ductal carcinomas (IDC). We found significant tissue and tumor subtype-specific differences in multiple cell types including T cells and neutrophils. Gene expression profiling of CD45 CD3 T cells demonstrated a decrease in CD8 signatures in IDCs. Immunofluorescence analysis showed fewer activated GZMB CD8 T cells in IDC than in DCIS, including in matched DCIS and recurrent IDC. T-cell receptor clonotype diversity was significantly higher in DCIS than in IDCs. Immune checkpoint protein TIGIT-expressing T cells were more frequent in DCIS, whereas high PD-L1 expression and amplification of (encoding PD-L1) was only detected in triple-negative IDCs. Coamplification of a 17q12 chemokine cluster with subdivided HER2 breast tumors into immunologically and clinically distinct subtypes. Our results show coevolution of cancer cells and the immune microenvironment during tumor progression. The design of effective cancer immunotherapies requires the understanding of mechanisms underlying immune escape during tumor progression. Here we demonstrate a switch to a less active tumor immune environment during the to invasive breast carcinoma transition, and identify immune regulators and genomic alterations that shape tumor evolution. .
ISSN:2159-8274
2159-8290
DOI:10.1158/2159-8290.CD-17-0222